Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
State-of-the-Art in Eye Cancer
share announcement

State-of-the-Art in Eye Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (15 November 2023) | Viewed by 3495

Special Issue Editors

Dr. Jan-Willem Beenakker

E-Mail Website
Guest Editor
Leiden University Medical Center, Albinusdreef 2, 2333ZA Leiden, The Netherlands
Interests: ocular oncology; magnetic resonance imaging; uveal melanoma; ocular proton therapy; ocular brachytherapy; physics; quantitative MRI; refractive surgery; ocular imaging
Dr. Jens Heufelder

E-Mail Website
Guest Editor
Charité – Universitätsmedizin Berlin, Klinik für Augenheilkunde and Berlin Protonen am Helmholtz-Zentrum Berlin für Materialien und Energie, Hahn-Meitner-Platz 1, 14109 Berlin, Germany
Interests: medical physics; ocular proton therapy; ocular radiation therapy; ocular brachytherapy; ocular treatment planning; dosimetry; treatment delivery
Dr. Marina Marinkovic

E-Mail Website
Guest Editor
Leiden University Medical Center, Albinusdreef 2, 2333ZA Leiden, The Netherlands
Interests: ophthalmology; ocular oncology; uveal melanoma; conjunctival melanoma; ocular proton therapy; ocular brachytherapy

Special Issue Information

Dear Colleagues,

Ocular oncology is a multidisciplinary field in which advances in imaging, radiotherapy, genetic and molecular understanding are combined to improve clinical outcomes. New imaging technologies, for example, give rise to the development of new strategies for ocular radiotherapy,  reducing post-treatment side effects. Meanwhile, the discovery of new genetic factors, such as the BAP1 tumor predisposition syndrome, has resulted in new clinical screening guidelines. Through these multidisciplinary efforts, our understanding and management of eye cancers, ranging from the eyelids and globe to the complete orbit, have significantly improved in recent years.

In this Special Issue of Cancers, the state of the art in eye cancer will be presented, with  special attention paid to the translation of scientific research between the different disciplines involved in ocular oncology.

Dr. Jan-Willem Beenakker
Dr. Jens Heufelder
Dr. Marina Marinkovic
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ocular oncology
  • uveal melanoma
  • retinoblastoma
  • lymphoma
  • eyelid
  • choroid
  • uvea
  • conjuctiva
  • orbit
  • ocular imaging
  • ocular radiotherapy
  • proton therapy
  • brachytherapy
  • pathology
  • multidisciplinary

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 1188 KiB  
Article
Incidence and Mortality of Uveal Melanoma in Hungary: A Nationwide Study
by Gábor Tóth, Béla Muzsik, Attila Szajkó, Pál Kerber, Elek Dinya, Béla Csákány, Zoltán Zsolt Nagy and János Németh
Cancers 2024, 16(5), 931; https://doi.org/10.3390/cancers16050931 - 25 Feb 2024
Viewed by 869
Abstract
Uveal melanoma (UM) is the most common primary malignant ocular tumour in adults, although its epidemiology in Central and Eastern Europe is unclear. This study aimed to analyse the incidence and all-cause mortality of UM in Hungary. This nationwide, retrospective, longitudinal study used [...] Read more.
Uveal melanoma (UM) is the most common primary malignant ocular tumour in adults, although its epidemiology in Central and Eastern Europe is unclear. This study aimed to analyse the incidence and all-cause mortality of UM in Hungary. This nationwide, retrospective, longitudinal study used data from the National Health Insurance Fund and included patients aged ≥18 years who were newly diagnosed with UM (ICD-10 C69.3 or C69.4) between 1 January 2012 and 31 December 2021. Age-standardised incidence and all-cause mortality rates were calculated using European Standard Population data from 2013. We identified 88 and 70 new patients with UM in 2012 and 2021, respectively, showing an almost stable trend. Age-standardised incidence rates varied between 6.40 and 10.96/1,000,000 person-years (PYs) during the analysed period. The highest age-standardised incidence was detected among men (13.38/1,000,000 PYs) in 2015. All-cause mortality decreased from 4.72/1,000,000 PYs to 0.79/1,000,000 PYs between 2012 and 2021. In conclusion, the UM incidence rate in Hungary is comparable to European incidence rates. The incidence did not markedly change, whereas all-cause mortality decreased during the study period, but this decline could not be attributed to improved treatment modalities for primary tumours and metastatic UM. Full article
(This article belongs to the Special Issue State-of-the-Art in Eye Cancer)
►▼ Show Figures

Figure 1

Other

Jump to: Research

20 pages, 2895 KiB  
Systematic Review
Magnetic Resonance Imaging in the Clinical Care for Uveal Melanoma Patients—A Systematic Review from an Ophthalmic Perspective
by Myriam G. Jaarsma-Coes, Lisa Klaassen, Marina Marinkovic, Gregorius P. M. Luyten, T. H. Khanh Vu, Teresa A. Ferreira and Jan-Willem M. Beenakker
Cancers 2023, 15(11), 2995; https://doi.org/10.3390/cancers15112995 - 30 May 2023
Cited by 3 | Viewed by 1985
Abstract
Conversely to most tumour types, magnetic resonance imaging (MRI) was rarely used for eye tumours. As recent technical advances have increased ocular MRI’s diagnostic value, various clinical applications have been proposed. This systematic review provides an overview of the current status of MRI [...] Read more.
Conversely to most tumour types, magnetic resonance imaging (MRI) was rarely used for eye tumours. As recent technical advances have increased ocular MRI’s diagnostic value, various clinical applications have been proposed. This systematic review provides an overview of the current status of MRI in the clinical care of uveal melanoma (UM) patients, the most common eye tumour in adults. In total, 158 articles were included. Two- and three-dimensional anatomical scans and functional scans, which assess the tumour micro-biology, can be obtained in routine clinical setting. The radiological characteristics of the most common intra-ocular masses have been described extensively, enabling MRI to contribute to diagnoses. Additionally, MRI’s ability to non-invasively probe the tissue’s biological properties enables early detection of therapy response and potentially differentiates between high- and low-risk UM. MRI-based tumour dimensions are generally in agreement with conventional ultrasound (median absolute difference 0.5 mm), but MRI is considered more accurate in a subgroup of anteriorly located tumours. Although multiple studies propose that MRI’s 3D tumour visualisation can improve therapy planning, an evaluation of its clinical benefit is lacking. In conclusion, MRI is a complementary imaging modality for UM of which the clinical benefit has been shown by multiple studies. Full article
(This article belongs to the Special Issue State-of-the-Art in Eye Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop